Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Tiotropium Easyhaler Variants vs Spiriva in Healthy Volunteers
NCT05246046Phase 1Completed
- Sponsor
- Orion Corporation
- Start
- Feb 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tiotropium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Orion Corporation. Primary endpoints: Peak tiotropium concentration in plasma, Area under the concentration-time curve from time zero to 30 minutes and 1 more. Started Feb 2022; status: completed.
02
Drugs
tiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05246046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05246046.